OECD Says Thailand's Ethanol Tax Rules Lag Behind Bioplastics Industry

Cosmo Oil announced on the 17th that it will begin utilizing naphtha co-produced in the SAF manufacturing process together with Maruzen Petrochemical, Ube-Maruzen Polyethylene, and SAFFAIRE SKY ENERGY. At the SAF production facility within Cosmo Oil's Sakai Refinery, naphtha obtained during the production of SAF from waste cooking oil will be utilized as a raw material for chemicals. SAFFAIRE SKY ENERGY will produce the naphtha, Cosmo Oil will supply it, Maruzen Petrochemical will produce basic chemicals, and Ube-Maruzen Polyethylene will produce polyethylene for development into plastic products. The four companies plan to expand supply volumes and develop applications going forward, aiming to contribute to decarbonization in the chemical, textile, and packaging sectors.

Global Green Chemicals Public Company Limited (GGC) and CP AXTRA Public Company Limited (CP AXTRA) have signed a memorandum of understanding to study the feasibility of collecting used cooking oil from CP AXTRA branches, as well as its group companies and network, to improve its quality and create new value in line with the circular economy concept. It is expected that approximately 50,000 liters of used cooking oil can be collected per year, to be used as feedstock for producing sustainable aviation fuel, bioplastics, and biochemicals. Dr. Krisada Prasertsukho, Managing Director of GGC, said that this collaboration is an important opportunity to study alternative feedstocks and add value from used resources. Meanwhile, Mrs. Siriporn Dechasingh, Chief Sustainability and Corporate Communications Officer of CP AXTRA, said that this collaboration reflects the practical application of circular economy principles, and if the study is successful, there is potential to expand into the production of sustainable aviation fuel, which would help reduce greenhouse gas emissions in the aviation sector.

Cathay Biotech disclosed its 2026 semi-annual report. In the first half, it achieved operating revenue of 1.9 billion yuan, up 13.73% year on year, and net profit attributable to shareholders of the listed company of 372 million yuan, up 20.75% year on year. The profit growth was mainly driven by continued volume expansion of long-chain dibasic acids and revenue contribution from new product sales. During the reporting period, bio-based sebacic acid and bio-based piperidine continued to be introduced to the market, bio-based azelaic acid entered the customer sampling stage, and long-chain polyamide modified products achieved large-scale sales. The company also led an investment in and increased its stake in the AI protein design company MoleculeMind, and currently holds about 17.43% of its shares, making it the largest external shareholder. At the same time, its self-built high-throughput research and development platform has entered the commissioning stage.